-
公开(公告)号：US12234276B2
公开(公告)日：2025-02-25
申请号：US17345553
申请日：2021-06-11
Applicant: Immatics Biotechnologies GmbH
Inventor： Andrea Mahr , Toni Weinschenk , Colette Song , Oliver Schoor , Jens Fritsche , Harpreet Singh
IPC: A61K38/00 , A61K35/17 , A61K38/17 , A61K39/00 , C07K7/06 , C07K14/47 , C07K14/725 , C07K14/74 , C07K16/28 , C12N5/0783 , C12N15/115 , C12Q1/6881 , G01N33/574 , A61K35/12 , C07K7/00
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US12186277B2
公开(公告)日：2025-01-07
申请号：US17743778
申请日：2022-05-13
Applicant: Immatics Biotechnologies GmbH
Inventor： Andrea Mahr , Toni Weinschenk , Colette Song , Oliver Schoor , Jens Fritsche , Harpreet Singh
IPC: A61K39/00 , A61K35/17 , C07K7/06 , C07K7/08 , C07K14/47 , C07K14/705 , C07K14/71 , C07K14/72 , C07K14/725 , C07K14/81 , C07K16/18 , C07K16/28 , C07K16/30 , C07K16/38 , C07K16/40 , C12N5/0783 , C12N9/02 , C12N9/12 , C12N15/115 , C12Q1/6886 , G01N33/574 , G16B25/00 , G16B25/10 , A61K38/00
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US12171819B2
公开(公告)日：2024-12-24
申请号：US17721573
申请日：2022-04-15
Applicant: Immatics Biotechnologies GmbH
Inventor： Andrea Mahr , Toni Weinschenk , Colette Song , Oliver Schoor , Jens Fritsche , Harpreet Singh
IPC: A61K38/00 , A61K39/00 , C07K7/06 , C07K7/08 , C07K14/47 , C07K14/705 , C07K14/71 , C07K14/72 , C07K14/725 , C07K14/81 , C07K16/18 , C07K16/28 , C07K16/30 , C07K16/38 , C07K16/40 , C12N5/0783 , C12N9/02 , C12N9/12 , C12N15/115 , C12Q1/6886 , G01N33/574 , G16B25/00 , G16B25/10 , A61K35/17
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US11999774B2
公开(公告)日：2024-06-04
申请号：US17314668
申请日：2021-05-07
Applicant: Immatics Biotechnologies GmbH
Inventor： Andrea Mahr , Toni Weinschenk , Colette Song , Oliver Schoor , Jens Fritsche , Harpreet Singh
IPC: C07K16/00 , A61K35/17 , A61K39/00 , C07K14/47 , C07K14/635 , C07K14/725 , C07K14/74 , C07K16/28 , C12N5/0783 , C12Q1/6886 , G01N33/574 , A61K38/00
CPC classification number: C07K14/70539 , A61K35/17 , A61K39/0011 , C07K14/4748 , C07K14/635 , C07K14/7051 , C07K16/2833 , C12N5/0638 , C12Q1/6886 , G01N33/57484 , A61K38/00 , A61K39/00 , C07K2319/70 , C12Q2600/156 , C12Q2600/158 , C12Q2600/16
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US11890333B2
公开(公告)日：2024-02-06
申请号：US17390583
申请日：2021-07-30
Applicant: Immatics Biotechnologies GmbH
Inventor： Sabrina Kuttruff-Coqui , Toni Weinschenk , Jens Fritsche , Steffen Walter , Norbert Hilf , Oliver Schoor , Colette Song , Harpreet Singh
IPC: C07K14/47 , C07K14/725 , C07K14/74 , C07K16/28 , C07K16/30 , A61P35/02 , A61P35/00 , A61K35/17 , A61K39/00 , C12N5/0783 , C07K14/705 , C07K7/06 , C07K7/08 , C12Q1/6886
CPC classification number: A61K39/0011 , A61K35/17 , C07K7/06 , C07K7/08 , C07K14/4748 , C07K14/705 , C07K14/70539 , C07K16/2833 , C12Q1/6886 , A61K2039/5158 , A61K2039/572 , A61K2039/80 , C07K2319/33 , C12Q2600/136 , C12Q2600/158 , C12Q2600/16
Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
Patent Agency Ranking
公开(公告)号：US11872270B2
公开(公告)日：2024-01-16
申请号：US17149397
申请日：2021-01-14
Applicant: Immatics Biotechnologies GmbH
Inventor： Colette Song , Linus Backert , Heiko Schuster , Daniel Johannes Kowalewski , Oliver Schoor , Jens Fritsche , Toni Weinschenk , Harpreet Singh
CPC classification number: A61K39/0011 , A61P35/00 , C07K7/06 , C07K16/2833 , C07K16/30 , A61K2039/5158 , C07K2317/32
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US11833193B2
公开(公告)日：2023-12-05
申请号：US17149241
申请日：2021-01-14
Applicant: Immatics Biotechnologies GmbH
Inventor： Colette Song , Linus Backert , Heiko Schuster , Daniel Johannes Kowalewski , Oliver Schoor , Jens Fritsche , Toni Weinschenk , Harpreet Singh
CPC classification number: A61K39/0011 , A61P35/00 , C07K7/06 , C07K16/2833 , C07K16/30 , A61K2039/5158 , C07K2317/32
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US11814446B2
公开(公告)日：2023-11-14
申请号：US17238932
申请日：2021-04-23
Applicant: IMMATICS BIOTECHNOLOGIES GMBH
Inventor： Toni Weinschenk , Steffen Walter , Jens Fritsche , Colette Song , Harpreet Singh
IPC: C07K7/06 , C07K7/08 , C12N5/0783 , C12N9/64 , A61K38/17 , A61K39/00 , A61K45/06 , C07K14/725
CPC classification number: C07K7/08 , A61K38/1709 , A61K39/0011 , A61K45/06 , C07K7/06 , C07K14/7051 , C12N5/0638 , C12N9/6491 , C12Y304/24065 , A61K2039/5158 , A61K2039/572 , C12N2502/11
Abstract: A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.
-
公开(公告)号：US11459366B2
公开(公告)日：2022-10-04
申请号：US17681107
申请日：2022-02-25
Applicant: Immatics Biotechnologies GmbH
Inventor： Colette Song , Oliver Schoor , Jens Fritsche , Toni Weinschenk , Harpreet Singh
IPC: A61K39/00 , C07K14/47 , C07K16/30 , C07K14/725 , C12N5/0783 , C12N15/10 , C12N15/115 , G01N33/574 , A61P35/00 , C07K16/28 , A61K35/17 , C07K7/06 , C07K14/54 , C07K14/74 , A61K38/00
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US11459365B2
公开(公告)日：2022-10-04
申请号：US17674910
申请日：2022-02-18
Applicant: Immatics Biotechnologies GmbH
Inventor： Colette Song , Oliver Schoor , Jens Fritsche , Toni Weinschenk , Harpreet Singh
IPC: A61K39/00 , C07K14/47 , C07K14/74 , C07K16/30 , C07K14/725 , C12N5/0783 , C12N15/10 , C12N15/115 , G01N33/574 , A61P35/00 , C07K16/28 , A61K35/17 , C07K7/06 , C07K14/54 , A61K38/00
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
-
-
-
-
-
-
-
-
Search Results
215
records
(took 0.042 seconds)
